Cancer testis (CT) antigens are an expanding family of tumor-associated antigens that have an highly tumor restricted expression pattern and a strong immunogenicity.
Among them, AKAP-4 was initially identified as an aberrantly expressed CTA in multiple myeloma primary cells (Chiriva-Internati et al. 2008).
Then AKAP4 expression has been demonstrated in various malignancies such as breast cancer (Saini et al. 2013), epithelial ovarian cancer (Agarwal et al. 2013 ; Kumar et al. 2017), cervix cancer (Agarwal et al. 2013), multiple myeloma (Chiriva-Internati et al. 2012), prostate cancer (Chiriva-Internati et al. 2012), in non-small cell lung carcinoma (NSCLC) (Mirandola et al. 2015 ; Mirandola et al. 2016) and in colon cancer (Jagadish et al. 2015 ; Jagadish et al. 2016 ; Tavakoli Koudehi et al. 2018). Furthermore, Kodehi and collaborators (2018) showed that AKAP4 expression was significantly correlated with liver metastasis in colon cancer, and may have therefore a potential as a pronostic biomarker in colon cancer.
Due to its expression in cancerous tissues and its potent immunogenicity, AKAP4 has been considered as a promising biomarker and immunotherapeutic candidate as for instance in breast (Jungbluth et al. 2000), in ovarian cancers (Agarwal et al. 2013) or in cervix cancer (Agarwal et al. 2013).
Discover our mouse monoclonal anti-AKAP4 antibody clone 7E10 (Ref. 4BDX-1602) as a biomarker. This antibody recognizes the carboxy-terminal region of A-kinase anchor protein 4 (AKAP4) and is suitable for Western Blot, for Immunohistochemistry, ELISA, Flow cytometry, Electron Microscopy and Immunofluorescence.